Literature DB >> 2169828

Treatment of hepatocellular carcinoma by segmental hepatic artery injection of adriamycin-in-oil emulsion with overflow to segmental portal veins.

H Nakamura1, T Hashimoto, H Oi, S Sawada, S Furui, S Mizumoto, M Monden.   

Abstract

Hepatocellular carcinoma was treated with slow injection of an emulsion containing 40 to 60 mg of adriamycin and 3.5 to 12 ml of Lipiodol into the portal vein via a segmental hepatic artery. During and after the injection, the portal branches of the segment were demonstrated. Six patients with resectable hepatocellular carcinoma received this treatment, which in 3 of them was followed by embolization with Gelfoam of the segmental artery. In these 3, all main tumors and daughter nodules became completely necrotic, but some infarction developed in the non-tumorous area. Those without Gelfoam had complete necrosis of all daughter nodules, but incomplete response of the main tumor. This combined treatment may be recommended for patients with localized lesions which are nonresectable due to cirrhosis, or for other reasons.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2169828

Source DB:  PubMed          Journal:  Acta Radiol        ISSN: 0284-1851            Impact factor:   1.990


  12 in total

1.  Segmental embolization by ethanol iodized oil emulsion for hepatocellular carcinoma.

Authors:  X Li; G Hu; P Liu
Journal:  J Tongji Med Univ       Date:  1999

2.  Outcome of localized hepatocellular carcinoma treated with segmental arterioportal chemoembolization.

Authors:  H Nakamura; H Oi; S Hori; Y Takayasu; S Furui; S Sawada; T Kozuka
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

3.  Liver parenchymal changes after transcatheter arterial embolization therapy for hepatoma: CT evaluation.

Authors:  Y Yamashita; M Torashima; T Oguni; A Yamamoto; M Harada; T Miyazaki; M Takahashi
Journal:  Abdom Imaging       Date:  1993

Review 4.  Transarterial chemoembolization for hepatocellular carcinoma: A review of techniques.

Authors:  Norihiro Imai; Masatoshi Ishigami; Yoji Ishizu; Teiji Kuzuya; Takashi Honda; Kazuhiko Hayashi; Yoshiki Hirooka; Hidemi Goto
Journal:  World J Hepatol       Date:  2014-12-27

5.  Transcatheter arterial embolization followed by percutaneous ethanol injection in the treatment of hepatocellular carcinoma.

Authors:  R Lencioni; C Vignali; D Caramella; R Cioni; S Mazzeo; C Bartolozzi
Journal:  Cardiovasc Intervent Radiol       Date:  1994 Mar-Apr       Impact factor: 2.740

Review 6.  Interventional treatment for unresectable hepatocellular carcinoma.

Authors:  Satoru Murata; Takahiko Mine; Fumie Sugihara; Daisuke Yasui; Hidenori Yamaguchi; Tatsuo Ueda; Shiro Onozawa; Shin-ichiro Kumita
Journal:  World J Gastroenterol       Date:  2014-10-07       Impact factor: 5.742

7.  Hepatocellular carcinoma: efficacy of transcatheter oily chemoembolization in relation to macroscopic and microscopic patterns of tumor growth among 100 patients with partial hepatectomy.

Authors:  T Hashimoto; H Nakamura; S Hori; K Tomoda; K Nakanishi; T Murakami; T Kozuka; M Monden; M Gotoh; C Kuroda
Journal:  Cardiovasc Intervent Radiol       Date:  1995 Mar-Apr       Impact factor: 2.740

8.  131I-labeled metuximab combined with chemoembolization for unresectable hepatocellular carcinoma.

Authors:  Qing He; Wu-Sheng Lu; Yang Liu; Yong-Song Guan; An-Ren Kuang
Journal:  World J Gastroenterol       Date:  2013-12-21       Impact factor: 5.742

9.  Comparison of epirubicin-iodized oil suspension and emulsion for transcatheter arterial chemoembolization in VX2 tumor.

Authors:  Tatsuo Ueda; Satoru Murata; Takahiko Mine; Shiro Onozawa; Munehiko Onda; Zenya Naito; Yasuo Amano; Shinichiro Kumita
Journal:  ScientificWorldJournal       Date:  2012-03-12

Review 10.  Transcatheter arterial chemoembolization based on hepatic hemodynamics for hepatocellular carcinoma.

Authors:  Satoru Murata; Takahiko Mine; Tatsuo Ueda; Ken Nakazawa; Shiro Onozawa; Daisuke Yasui; Shin-ichiro Kumita
Journal:  ScientificWorldJournal       Date:  2013-03-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.